

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to

PATENT
Attorney Docket No.: 021044-000600US 8/3/02

Assistant Commissioner for Patents
Washington, D.C. 20231

On June 21, 2002
TOWNSEND and TOWNSEND and CREW LLP
By [Signature]

RECEIVED
JUL 08 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Masuda et al.

Application No.: 09/998,667

Filed: December 3, 2001

For: TRAC1: MODULATORS OF
LYMPHOCYTE ACTIVATION

PETITION TO CORRECT
INVENTORSHIP UNDER
37 C.F.R. § 1.48

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants petition under 37 C.F.R. § 1.48 to add Congfen Li as an inventor of the above-identified patent application.

As required by 37 C.F.R. § 1.48, the following are submitted herewith:

- (1) Statement from Congfen Li stating that it was through error without deceptive intent that she was not named as an inventor in the above-identified patent application;
- (2) Written consent from the assignee, Rigol Pharmaceuticals, Inc.
- (3) A supplemental declaration signed by Congfen Li.

07/02/2002 SSESHE1 00000019 201430 09998667

01 FC:122

130.00 CH



COPY OF PAPERS
ORIGINALLY FILED

Please deduct the petition fee, pursuant to 37 C.F.R. § 1.17(i), from Deposit Account No. 20-1430 of the undersigned. Please charge any additional fees or credit overpayment to the above Deposit Account.

Respectfully submitted,



Annette S. Parent
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200/Fax: (415) 576-0300

SF 1349050 v1